

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/722,184	11/25/2003	Jeffrey O. Phillips	03207556	7922
26565 75	590 01/09/2006		EXAMINER	
MAYER, BROWN, ROWE & MAW LLP			CHANG, CELIA C	
P.O. BOX 2828 CHICAGO, IL 60690-2828			ART UNIT	PAPER NUMBER
ŕ			1625	

DATE MAILED: 01/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/722,184	PHILLIPS, JEFFREY O.
Office Action Summary	Examiner	Art Unit
	Celia Chang	1625
 The MAILING DATE of this communication app Period for Reply 	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on <u>21 Ju</u> This action is FINAL . 2b) ☑ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. see except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 151-218 is/are pending in the applicat 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 151-218 are subject to restriction and/	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner	epted or b) objected to by the lidrawing(s) be held in abeyance. See on is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive i (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

Application/Control Number: 10/722,184 Page 2

Art Unit: 1625

DETAILED ACTION

1. A preliminary amendment was filed on July 21, 2005. Claims 1-150 have been canceled. Claims 151-218 are pending.

2. Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 157, 159 and claims 151-156, 160-170, 174-210 reading on omeprazole, drawn to composition containing omeprazole, classified in class 514, subclass 339.
- II. Claim 158 and claims 151-156, 160-170, 174-210 reading on lansoperazole, drawn to composition containing lansoprazole, classified in class 514, subclass 340.
- III. Claims 151-156, 160-170, 174-210, drawn to composition of the remaining subject matter, classified in class various, subclass various, depending on species election. If this group is elected, a further election of a single disclosed species of composition with the proton pump inhibitor and buffering agent explicitly named is also required.
- IV. Claims 171-172, drawn to multiple active ingredient compositions, classified in class various, subclass various, depending on species election. If this group is elected, a further election of a single disclosed species of composition with the proton pump inhibitor, buffering agent and the further active ingredient i.e. antibacterial agent, etc. explicitly named is also required.

Application/Control Number: 10/722,184

Art Unit: 1625

V. Claims 212-214 and 173, 215-218 in part reading on omerpazole, drawn to liquid dosage formulation, classified in class 514, subclass 339.

Page 3

VI. Claims 173, 215-218, drawn to liquid dosage formulation, classified in class 514, subclass various, depending on species election. If this group is elected, a further election of a single disclosed species of liquid formula with the proton pump inhibitor and buffering agent and liquid carrier explicitly named is also required.

The inventions are distinct, each from the other because of the following reasons:

Each group of invention contain patentably independent and distinct material including proton pump inhibitor, buffering agent and other active ingredient. Unpatentability of any one group of invention does not necessarily mean unpatentability of the other groups of invention. A search for each group for its specific elements of the composition would not be required for another group which does not have the identical elements of the composition, thus, is not coextensive. The merit of each invention depends on the specific element, carrier and dosage of each composition, thus, must be searched, and examined independently.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Should applicant traverse on the ground that the groups are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the groups to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention. In the instant case, then

Art Unit: 1625

there could have been no patentability of all the claims over US 5,447,918, see col. 14, lines 55-68 example 7 containing omerprazole and calcium carbonate which anticipated group I invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang Jan. 5, 2006 Celia Chang
Primary Examiner
Art Unit 1625